ALSO NOTED: ISTO wraps financing deal; Chiron facility found acceptable; Pharmaxis trial hits endpoint; and much more...

> St. Louis-based ISTO Technologies has completed a $10.8 million financing package. Release

> Chiron announced that an FDA inspection of its Liverpool facility found that it was "generally acceptable." Release

> Australia's Pharmaxis announced that a Phase II trial of Bronchitol in patients with cystic fibrosis hit its primary endpoint of improved lung function. Release

> Researchers say that low blood flow to the brain may be a cause of dementia. Article

And Finally... From the team at FierceMarkets: Our hearts go out to the victims of Hurricane Katrina. If you have not done so, please think about donating money and/or time to a charity like the American Red Cross. We offer our best wishes to the individuals and businesses in the Gulf Coast region who will be recovering from this disaster in the months to come.

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.